Tribunnews Reporter, Fitri Wulandari
TRIBUNNEWS.COM, LONDON – An experimental long-acting combo antibody therapy developed by the Anglo-Swedish pharmaceutical giant AstraZeneca claimed to have helped reduce the risk of disease corona virus (Covid-19) or death.
This is when compared with placebo received by patients who are not hospitalized with mild to moderate disease symptoms.
This statement was made by the company on Monday local time.
Quoted from the page Sputnik News, Tuesday (12/10/2021), the AZD7442 therapy given by injection, uses a mixture of two antibodies called tixagevimab (AZD8895) and cilgavimab (AZD1061) and is designed to protect people who do not have a strong enough immune response to the vaccine.
As Professor of Intensive Care Medicine at University College London who is the principal investigator of the study known as TACKLE, Hugh Montgomery, said.
Also read: Japanese Professor: Antibody Cocktail Therapy Blocks Viruses From Reproducing in the Body
“With the continuing cases of infection Covid-19 worldwide, there is a significant need for new therapies such as AZD7442 that can be used to protect vulnerable populations Covid-19 and can also help prevent the development of severe disease,” says Montgomery.
These scientists later delivered positive results showing that a convenient intramuscular dose of AZD7442 could play an important role in helping to combat the pandemic.
AstraZeneca, which developed the vaccine Covid-19 together with the University of Oxford, said the cocktail trial involved more than 900 adults in 13 countries.
Later, the results will be submitted for publication in a peer-reviewed medical journal.
AstraZeneca has also requested authorization from the US Food and Drug Administration (FDA) for emergency use.
–
